NIX by GSK is clinical pharmacology: the pharmacokinetics (pk) of florfenicol (table 1) and flunixin (table 2) after subcutaneous injection of florfenicol and flunixin meglumine is described below: image of pharmacokinetic parameters table. Approved for bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and 3 more indications. First approved in 1986.
Drug data last refreshed 3m ago · AI intelligence enriched 1w ago
NIX is a topical lotion combination product containing florfenicol and flunixin meglumine approved in 1986 for bovine respiratory disease (BRD) in cattle. It treats BRD caused by multiple pathogens including Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis, while controlling associated fever. The florfenicol component is a broad-spectrum antibiotic and flunixin is an NSAID that reduces pyrexia.
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting defensive commercial operations and possible cost-containment focus.
CLINICAL PHARMACOLOGY: The pharmacokinetics (PK) of florfenicol (Table 1) and flunixin (Table 2) after subcutaneous injection of florfenicol and flunixin meglumine is described below: image of pharmacokinetic parameters table
Worked on NIX at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment
Project PHOENIX: Molecular Signatures of Burn Pit Exposure
PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC
Augmented Reality BCI Longitudinal Study for Persons With ALS, Stroke, TBI and SCI Utilizing Cognixion + Apple Vision Pro
Pilot Study of PHOENIX Wound Matrix® Impact on Chronic DFU Wound Microbiome
GSK is hiring 4 roles related to this product
Working on NIX offers experience in mature product stewardship and defensive portfolio management within animal health, a niche but stable therapeutic area under GSK ownership. Career progression likely centers on market defense, customer retention, and cost-efficiency rather than launch-phase growth opportunities.